Zanubrutinib ( DrugBank: Zanubrutinib )


5 diseases
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica1
63Idiopathic thrombocytopenic purpura2
222Primary nephrotic syndrome1
300IgG4-related disease1
331Idiopathic multicentric castleman disease1

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,340Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

63. Idiopathic thrombocytopenic purpura


Clinical trials : 391Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

222. Primary nephrotic syndrome


Clinical trials : 310Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

300. IgG4-related disease


Clinical trials : 40Drugs : 47 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 141 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

331. Idiopathic multicentric castleman disease


Clinical trials : 33Drugs : 41 - (DrugBank : 21) / Drug target genes : 22 - Drug target pathways : 123 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries